Profound Changes in Lipid-Lowering Therapy Coming with New Agents Targeting LP(a) and Triglycerides

Our understanding of lipid pathology is shifting from what might be called the “LDL hypothesis” to the “atherogenic lipoprotein hypothesis.” LDL is just a surrogate of the actual process of lipoprotein interaction with the arterial wall. This shift in understanding is driving a host of budding therapies with novel approaches to targeting key atherogenesis players like lipoprotein(a) and triglycerides.